Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women

被引:98
作者
Barinas-Mitchell, E
Cushman, M
Meilahn, EN
Tracy, RP
Kuller, LH
机构
[1] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA
[2] Univ Vermont, Dept Med, Burlington, VT USA
[3] Univ Vermont, Dept Pathol, Burlington, VT USA
[4] Univ Vermont, Dept Pathol, Colchester, VT USA
[5] Univ Vermont, Dept Biochem, Colchester, VT USA
关键词
adipose tissue; estrone; hormone replacement therapy; inflammation; women;
D O I
10.1093/aje/153.11.1094
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The authors evaluated the cross-sectional and prospective associations between the serum concentration of C-reactive protein and measures of obesity and fat distribution, hormone replacement therapy (HRT) use, and serum sex hormones in postmenopausal women from the Healthy Women Study (Allegheny County, Pennsylvania, 1998). The authors tested the hypothesis that C-reactive protein levels would be higher among HRT users and among women with greater body mass index, waist circumference, or visceral fat. There were 207 women in the study who were greater than or equal to8 years postmenopausal (101 HRT users and 106 HRT nonusers). The median levels of C-reactive protein were 3.01 mg/liter in HRT users compared with 1.74 mg/liter in nonusers (p = 0.002). C-reactive protein levels were strongly positively correlated with measures of body size, fatness, fat distribution, and weight gain among HRT users and nonusers. C-reactive protein was also positively correlated with serum estrone levels (r(s) = 0.38) among HRT nonusers. The highest level of C-reactive protein was found among HRT users in the highest quartile of visceral fat (4.29 mg/liter) compared with women not on HRT and in the lowest quartile of visceral fat (0.96 mg/liter). The use of HRT and measures of overall body fatness are important correlates of C-reactive protein among postmenopausal women.
引用
收藏
页码:1094 / 1101
页数:8
相关论文
共 38 条
[1]  
Bastard JP, 1999, CIRCULATION, V99, P2221
[2]   Hormone replacement therapy, inflammation, and hemostasis in elderly women [J].
Cushman, M ;
Meilahn, EN ;
Psaty, BM ;
Kuller, LH ;
Dobs, AS ;
Tracy, RP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (04) :893-899
[3]   Effect of postmenopausal hormones on inflammation-sensitive proteins - The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study [J].
Cushman, M ;
Legault, C ;
Barrett-Connor, E ;
Stefanick, ML ;
Kessler, C ;
Judd, HL ;
Sakkinen, PA ;
Tracy, RP .
CIRCULATION, 1999, 100 (07) :717-722
[4]   RAISED C-REACTIVE PROTEIN-LEVELS IN SERUM FROM SMOKERS [J].
DAS, I .
CLINICA CHIMICA ACTA, 1985, 153 (01) :9-13
[5]   ASSESSMENT OF ADIPOSE-TISSUE DISTRIBUTION BY COMPUTED AXIAL-TOMOGRAPHY IN OBESE WOMEN - ASSOCIATION WITH BODY DENSITY AND ANTHROPOMETRIC MEASUREMENTS [J].
FERLAND, M ;
DESPRES, JP ;
TREMBLAY, A ;
PINAULT, S ;
NADEAU, A ;
MOORJANI, S ;
LUPIEN, PJ ;
THERIAULT, G ;
BOUCHARD, C .
BRITISH JOURNAL OF NUTRITION, 1989, 61 (02) :139-148
[6]   Body mass index, diabetes, and C-reactive protein among US adults [J].
Ford, ES .
DIABETES CARE, 1999, 22 (12) :1971-1977
[7]  
Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5
[8]   C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men -: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 [J].
Koenig, W ;
Sund, M ;
Fröhlich, M ;
Fischer, HG ;
Löwel, H ;
Döring, A ;
Hutchinson, WL ;
Pepys, MB .
CIRCULATION, 1999, 99 (02) :237-242
[9]  
Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963
[10]   RELATIONSHIP OF ENDOGENOUS SEX STEROID-HORMONES TO LIPIDS AND APOPROTEINS IN POSTMENOPAUSAL WOMEN [J].
KULLER, LH ;
GUTAI, JP ;
MEILAHN, E ;
MATTHEWS, KA ;
PLANTINGA, P .
ARTERIOSCLEROSIS, 1990, 10 (06) :1058-1066